Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K2 | Q12851 | 17/20 | 0.78 |
| ▸ | TNK2 | Q07912 | 16/20 | 0.78 |
| ▸ | BMX | P51813 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134211 | 0.96 | TNK2 (0.84) | MAP4K2TNK2BMXABL1EGFR | |
| SCHEMBL3139861 | 0.95 | TNK2 (0.78) | MAP4K2TNK2BMXABL1EGFR | |
| SCHEMBL3139872 | 0.93 | TNK2 (0.75) | MAP4K2TNK2BMXABL1EGFR | |
| SCHEMBL3127005 | 0.92 | TNK2 (0.74) | MAP4K2TNK2BMXABL1EGFR | |
| SCHEMBL3132208 | 0.91 | TNK2 (0.74) | MAP4K2TNK2BMXABL1 | |
| SCHEMBL13523337 | 0.91 | TNK2 (0.64) | MAP4K2TNK2BMXABL1 | |
| SCHEMBL25735971 | 0.89 | TNK2 (0.70) | MAP4K2TNK2BMXABL1 | |
| SCHEMBL3143346 | 0.89 | TNK2 (0.67) | MAP4K2TNK2BMXABL1 | |
| SCHEMBL3137490 | 0.88 | TNK2 (0.68) | MAP4K2TNK2BMXABL1 | |
| SCHEMBL3132781 | 0.88 | TNK2 (0.80) | MAP4K2TNK2BMXABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | claimed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | claimed |
| JP-2007500725-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | claimed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | MAP4K2 37/4885TNK2 203/4885BMX 1/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | MAP4K2 37/4885TNK2 203/4885BMX 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.